NanoViricides Reports HIVCide Exhibited Long Term Sustained Anti-HIV Effects Even After Drug Discontinuation

WEST HAVEN, Conn.--(BUSINESS WIRE)--Aug 15, 2011 -
NanoViricides, Inc. (OTCBB:
NNVC) (the "Company") reports that its lead anti-HIV drug
candidate achieved a long term anti-HIV effect with a much shorter
dosing regimen and a markedly lower total drug dose than HAART drug
cocktail therapy in a recent animal study. The antiviral effect of
the anti-HIV nanoviricide (“HIVCide™”) continued
throughout the 48 days of study even though HIVCide dosing was
discontinued after only 20 days.

The clinical benefit of HIVCide was found to be sustained for at
least four weeks after the last drug dose. Treatment with the lead
anti-HIV nanoviricide both (1) reduced the HIV viral load and (2)
also protected the human T cells
(CD4+,CD8+), equally well as
compared to treatment with the three-drug HAART cocktail, at
24-days as well as at 48-days, even though the HIVCide treatment
was stopped at 20 days.

The Company believes that achieving this sustained clinical
benefit after stopping nanoviricide treatment is highly
significant. A similar sustained reduction in viral load even after
discontinuation of the drug was also observed for the Company's
previously reported anti-influenza FluCide™ lead drug
candidate. Such sustained, prolonged clinical effects can be
expected on the basis of the design of nanoviricides. A
nanoviricide is made from a polymeric micelle structure that is
designed to provide long circulating half-life in the body that
should enable sustained therapeutic effectiveness.

In addition, the lead HIVCide drug candidate provided these
clinical benefits at a much lower drug load than that of the HAART
therapy. The HIVCide total dose was 1,200 mg/kg while the HAART
cocktail dose was 4,800 mg/kg. The HIVCide candidate was dosed only
8 times in the first 20 days after HIV infection. HIVCide treatment
was stopped after 20 days. In contrast, in the comparator group,
HAART cocktail treatment continued for the entire 48 days. The HIV
viral load was markedly reduced to the same extent in both the
HIVCide-treated mice and the HAART-treated mice throughout the 48
days study. In addition, the “double positive”,
CD4+,CD8+, human T cells were protected to similar extents in the
HIVCide and HAART treatment groups, throughout the duration of the
study.

There were no side effects or adverse effects observed for the
HIVCide therapy group.

The Company believes that it has achieved extremely high
efficacy levels for its lead HIVCide candidate. The current study
was designed to identify the best ligand that would help the
nanomicelle attack HIV most efficiently. Further optimization is
under way to improve the effectiveness of the nanomicelle backbone
itself against HIV. In a similar optimization strategy, the Company
has previously reported extremely strong improvements in its highly
successful optimization of the anti-influenza nanoviricide in the
FluCide™ program.

It is also important to emphasize that mouse drug metabolism is
known to be much faster than human metabolism. Thus, if HIVCide
therapy is effective in HIV-infected humans, a sustained clinical
benefit can be envisioned with intermittent HIVCide treatment.

The Company believes that HIVCide may enable a once-a-week or
possibly even twice-a-month treatment, if the results of this
humanized mouse study can be extrapolated to humans.

"It's been more than 30 years since I saw my first patient who
turned out to have HIV/AIDS," said Eugene Seymour, MD, MPH, CEO,
adding, "Since then I've always dreamt of the day a drug like ours
would come along. There are several huge problems with the current
HIV therapy. These include side effects, viral resistance, and
patient compliance issues; all of which can lead to discontinuation
of therapy. A drug that is administered once a week or less
frequently, and continues to work without adverse side effects,
would be of great benefit to patients. If our humanized mouse study
results are confirmed in human clinical trials, this would be a
great advance in HIV/AIDS therapy. If the results hold up in human
studies, we think that we would have a ˜functional cure' of
HIV/AIDS.”

The study was performed in the standard anti-HIV animal model
known as the "SCID/hu Thy/Liv mouse model." In this model, human
lymphocytes and immune system cells replace the mouse immune
system. Thus the HIV infection occurs into the human cells
implanted in the mouse “test tube.” HIV viral load and
human T cell population assessments were performed at 24 days as
well as at 48 days after HIV infection.

There was no change in treatment of animals after 21 days (i.e.
after HIVCide was stopped). Therefore, the assessments at 24 days
and 48 days, taken together, can reasonably be expected to
represent the time course of the duration of study.

The study was performed at KARD Scientific, Inc., Beverly, MA,
in a Bio-Safety Level 3 (BSL-3) facility under the guidance of Dr.
Krishna Menon who has extensive experience in pre-clinical
evaluation of drug candidates in disease-relevant animal models.
The three drug HAART cocktail used for comparison in this study is
one of the combination therapies recommended for initial therapy in
humans, viz. AZT, 3TC and Efavirenz. Other specific results of this
study were previously reported by the Company.

NanoViricides, Inc. (www.nanoviricides.com)
is a development stage company that is creating special purpose
nanomaterials for viral therapy. The Company's novel
nanoviricide™ class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.

This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking
statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. You should not place undue reliance on forward-looking
statements since they involve known and unknown risks,
uncertainties and other factors which are, in some cases, beyond
the Company's control and which could, and likely will, materially
affect actual results, levels of activity, performance or
achievements. The Company assumes no obligation to publicly update
or revise these forward-looking statements for any reason, or to
update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new
information becomes available in the future. Important factors that
could cause actual results to differ materially from the company's
expectations include, but are not limited to, those factors that
are disclosed under the heading "Risk Factors" and elsewhere in
documents filed by the company from time to time with the United
States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all
such factors, they may include the following: demonstration and
proof of principle in pre-clinical trials that a nanoviricide is
safe and effective; successful development of our product
candidates; our ability to seek and obtain regulatory approvals,
including with respect to the indications we are seeking; the
successful commercialization of our product candidates; and market
acceptance of our products.